alexa Verxve 144-Week Results: Nevirapine Extended Release (NVP XR) Qd Versus NVP Immediate Release (IR) Bid with FTC/TDF in Treatment-Naive HIV-1 Patients | Abstract
ISSN 2155-6113

Journal of AIDS & Clinical Research
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Verxve 144-Week Results: Nevirapine Extended Release (NVP XR) Qd Versus NVP Immediate Release (IR) Bid with FTC/TDF in Treatment-Naive HIV-1 Patients

Brinson C1*, Bogner JR2, Nelson M3, Podzamczer D4, Quinson AM5, Drulak M5, Andrade-Villanueva J6, Cahn P7, Santiago S8 and Gathe J9

1Central Texas Clinical Research, Austin, TX, USA

2University Hospital of Munich, Munich, Germany

3St Stephen’s AIDS Trust, London, UK

4Hospital Universitari de Bellvitge, Barcelona, Spain

5Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA

6Universidad de Guadalajara, Guadalajara, Mexico

7Fundación Huspéd, Buenos Aires, Argentina

8Care Resource, Miami, FL, USA

9Therapeutic Concepts, Houston, TX, USA

*Corresponding Author:
Cynthia Brinson
Central Texas Clinical Research
Austin, TX 78751
Tel: 512-480-9270
E-mail: [email protected]

Received Date: June 24, 2013; Accepted Date: August 20, 2013; Published Date: August 25, 2013

Citation: Brinson C, Bogner JR, Nelson M, Podzamczer D, Quinson AM, et al. (2013) Verxve 144-Week Results: Nevirapine Extended Release (NVP XR) Qd Versus NVP Immediate Release (IR) Bid with FTC/TDF in Treatment-Naïve HIV-1 Patients. J AIDS Clin Res 4:233. doi:10.4172/2155-6113.1000233

Copyright: © 2013 Brinson C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Background: We report 96- and 144-week follow-up data from VERxVE, demonstrating that nevirapine (NVP) extended release (XR) 400 mg once daily was non-inferior to NVP immediate release (IR) 200 mg twice daily, each administered on a backbone of emtricitabine/tenofovir. Methods: VERxVE was a double-blind, double-dummy, non-inferiority study in adults with screening viral load (VL) >1000 copies/mL and CD4+ cell count <400 cells/mm3 (males) or <250 cells/mm3 (females). Randomisation was stratified by baseline VL (copies/mL) ≤ 100,000 or >100,000. The primary endpoint was confirmed virologic response (<50 copies/mL) at week 48. Cochran’s statistic incorporating baseline VL strata tested non-inferiority of XR efficacy versus IR. Secondary endpoints included 144-week sustained virologic response and safety. Results: In all, 1011 patients were randomised and treated with NVP: 736 (XR n=378; IR n= 358) completed 144 weeks. Virologic response was 63.6% for NVP XR and 58.5% for NVP IR (adjusted difference of 4.8% [95% confidence interval –1.1% to 10.8%] favouring NVP XR). No significant differences were seen in changes in CD4+ T-cell counts from baseline, virologic failures or total discontinuation rates between treatment arms, regardless of demographic or baseline characteristics. Conclusions: NVP XR demonstrated non-inferior virologic efficacy to NVP IR in treatment-naïve HIV-infected patients and was well tolerated out to week 144, with a safety profile similar to NVP IR.


Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version